<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Chronic obstructive pulmonary disease: Prognostic factors and comorbid conditions</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Chronic obstructive pulmonary disease: Prognostic factors and comorbid conditions</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Chronic obstructive pulmonary disease: Prognostic factors and comorbid conditions</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Scott T Weiss, MD, MS</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">James K Stoller, MD, MS</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Dieffenbach, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 08, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>A variety of clinical factors are thought to influence the natural history and prognosis of patients with chronic obstructive pulmonary disease (COPD) [<a href="#rid1">1-3</a>]. These factors and the impact of acute exacerbations and comorbidities on disease outcome will be reviewed here.</p><p>The diagnosis and management of COPD are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/1455.html" rel="external">"Chronic obstructive pulmonary disease: Diagnosis and staging"</a> and  <a class="medical medical_review" href="/d/html/1461.html" rel="external">"COPD exacerbations: Management"</a> and  <a class="medical medical_review" href="/d/html/1447.html" rel="external">"Stable COPD: Initial pharmacologic management"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">PROGNOSTIC FACTORS</span><span class="headingEndMark"> — </span>A number of factors have been identified as prognostic indicators for COPD. The forced expiratory volume in one second (FEV<sub>1</sub>), a measure of severity of airflow limitation is most often used; other predictors of accelerated lung function decline, diminished physical function, and/or mortality in patients with COPD include the following [<a href="#rid4">4-18</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Airways responsiveness</p><p class="bulletIndent1"><span class="glyph">●</span>Cigarette smoking</p><p class="bulletIndent1"><span class="glyph">●</span>Low body-mass index (BMI ≤21)</p><p class="bulletIndent1"><span class="glyph">●</span>Human immunodeficiency virus (HIV) infection</p><p class="bulletIndent1"><span class="glyph">●</span>Increased airway bacterial load</p><p class="bulletIndent1"><span class="glyph">●</span>Decreased exercise capacity</p><p class="bulletIndent1"><span class="glyph">●</span>Diffusing capacity for carbon monoxide (DLCO)</p><p class="bulletIndent1"><span class="glyph">●</span>Peak oxygen consumption (VO<sub>2</sub>), measured by cardiopulmonary exercise testing</p><p class="bulletIndent1"><span class="glyph">●</span>Elevated C-reactive protein (&gt;3 mg/L)</p><p class="bulletIndent1"><span class="glyph">●</span>Male sex</p><p class="bulletIndent1"><span class="glyph">●</span>Chest computed tomography (CT) showing presence or progression of emphysema or mucus plugging</p><p></p><p class="headingAnchor" id="H20085935"><span class="h2">Forced expiratory volume in one second</span><span class="headingEndMark"> — </span>The FEV<sub>1</sub> is the parameter most commonly used to assess the severity of COPD and to predict future changes in lung function and survival [<a href="#rid19">19-23</a>]. The change in FEV<sub>1</sub> over time has been assessed in several studies and is affected by smoking status, but is highly variable among individual patients [<a href="#rid20">20,24,25</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>In a three-year study, the changes in the FEV<sub>1</sub> measured after administration of bronchodilator were assessed in 2163 subjects with COPD [<a href="#rid20">20</a>]. The overall rate of decline was 33 mL per year, although almost 40 percent of the subjects had a decline of more than 40 mL per year. A high variability in the rate of decline in FEV<sub>1</sub> was noted, with higher rates in current smokers (54 mL per year), patients with bronchodilator reversibility, and patients with emphysema on CT.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the United States Lung Health Study, the rate of decline in post-bronchodilator FEV<sub>1</sub> was assessed in 5887 smokers with mild to moderate COPD [<a href="#rid21">21</a>]. The unadjusted annual decline was 53.1 mL/year at year 5 and 53.9 mL/year by year 12, by which time 46 percent were still active smokers.</p><p></p><p>The postbronchodilator FEV<sub>1</sub> has also been used to predict survival [<a href="#rid19">19</a>]. Among 200 patients with COPD, who were followed for 15 years, after controlling for age, the postbronchodilator FEV<sub>1</sub> was the best predictor of survival  (<a class="graphic graphic_table graphicRef61524" href="/d/graphic/61524.html" rel="external">table 1</a>). However, wide individual variability in prognosis was noted.</p><p class="headingAnchor" id="H3"><span class="h2">BODE index</span><span class="headingEndMark"> — </span>A multidimensional index (the BODE index) was developed to assess an individual's risk of death from COPD. The four factors included in the index are weight (BMI), airway obstruction (FEV<sub>1</sub>), dyspnea (Medical Research Council dyspnea score), and exercise capacity (six-minute walk distance) (<a class="calc calc_professional" href="/d/html/13448.html" rel="external">calculator 1</a>). The BODE index is superior for prediction of mortality compared with unidimensional assessment based on the FEV<sub>1</sub> value alone [<a href="#rid4">4,12</a>]. The utility of the BODE index is not confined to assessing the risk of death; it can also predict hospitalization [<a href="#rid26">26</a>].</p><p>The majority of patients with COPD have a stable BODE index over time, as demonstrated in a longitudinal study of 751 patients who were followed for a median of 64 months [<a href="#rid24">24</a>]. A statistically significant decrease in the BODE index was noted in 18 percent, the BODE index remained stable in 68 percent, and the BODE index increased in 14 percent. Patients with an increase in the BODE index had more severe obstruction at baseline than those with a stable BODE index.</p><p>A modified BODE (mBODE) index uses an alternate dyspnea questionnaire (ie, UCSD SOBQ) and is a better predictor of mortality than its separate components [<a href="#rid27">27</a>]. (See  <a class="medical medical_review" href="/d/html/1455.html" rel="external">"Chronic obstructive pulmonary disease: Diagnosis and staging", section on 'Assessment of severity and staging'</a>.)</p><p class="headingAnchor" id="H4"><span class="h2">Body mass</span><span class="headingEndMark"> — </span>BMI is an independent risk factor in COPD. Decreasing body mass is associated with increasing mortality [<a href="#rid28">28-30</a>]. Further weight loss increases mortality risk, whereas weight gain improves prognosis [<a href="#rid31">31,32</a>].</p><p>The fat-free mass index (FFMI) provides information beyond that provided by the BMI.</p><p class="bulletIndent1"><span class="glyph">●</span>The FFMI can identify a subgroup of patients with an increased mortality risk despite a normal BMI. This was illustrated by a prospective cohort study of 1898 patients with COPD who were followed for a mean of seven years [<a href="#rid33">33</a>]. Both BMI and FFMI were predictors of mortality. Among patients with a normal BMI, FFMI was a predictor of mortality (26 percent had an FFMI lower than the tenth percentile).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The FFMI is a better predictor of disease severity. While both BMI and FFMI correlate with the six-minute walk test, only FFMI correlates with the degree of chronic dyspnea, the FEV<sub>1</sub>, the FEV<sub>1</sub>/forced vital capacity (FVC) ratio, or the stage of disease, according to one observational study [<a href="#rid34">34</a>]. A larger study verified a strong correlation between FFMI and 6MWD in underweight patients [<a href="#rid35">35</a>]. Furthermore, compared with BMI, stratification by FFMI demonstrated improved classification of patients according to lung function, exercise capacity, physical activity, quality of life, and respiratory symptoms. Interestingly, FFMI was <strong>not </strong>useful as a marker of disease severity in obese patients.</p><p></p><p class="headingAnchor" id="H986129296"><span class="h2">Mucus plugging</span><span class="headingEndMark"> — </span>Excess production, hypersecretion, and reduced clearance of mucus in the airways lead to an accumulation of mucus plugs in the lungs of patients with COPD [<a href="#rid36">36</a>]. There is growing evidence that mucus plugging in both the small and large airways impacts prognosis independently of other clinical risk factors.</p><p>The presence of mucus plugging on CT imaging is associated with airway obstruction independently of emphysema and correlates with lower oxygen saturations, reduced exercise capacity, and lower respiratory quality of life [<a href="#rid37">37,38</a>]. For most patients with mucus plugging, the airway blockages persist on repeated CT scans, and up to 30 percent of patients with mucus plugging do not report symptoms of chronic bronchitis.</p><p>The degree of mucus plugging in both large and small airways is independently associated with increased mortality [<a href="#rid39">39,40</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In one study, 4363 patients with COPD were evaluated for baseline mucus plugging in medium to large airways (2 to 10 mm in diameter) using submillimeter resolution CT scans with enhancing algorithms and followed for a median of 9.5 years [<a href="#rid40">40</a>]. After adjusting for age, sex, BMI, race/ethnicity, smoking status and history, degree of airway obstruction, and CT measures of emphysema and airway wall thickness, mucus plugging showed an independent association with all-cause mortality (adjusted hazard ratio 1.15 and 1.24 for mucus plugs affecting one to two lung segments and ≥3 lung segments compared with zero segments, respectively). These associations were similar even after further adjusting for chronic bronchitis, BODE index, or concomitant asthma, but they were modestly attenuated after inclusion of exacerbation history.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a separate study of 101 patients with severe COPD undergoing surgical lung volume reduction, histologically verified mucus plugging in the small (&lt;2 mm diameter) airways was associated with earlier mortality (highest versus lowest quartile HR 3.3, 95% CI 1.5-6.9) [<a href="#rid39">39</a>]. This association was not influenced by correcting for age, level of respiratory symptoms, or level of expiratory flow limitation.</p><p></p><p class="headingAnchor" id="H5"><span class="h2">Airway hyperresponsiveness and bronchodilator response</span><span class="headingEndMark"> — </span>Airway hyperresponsiveness (eg, <a class="drug drug_general" data-topicid="9622" href="/d/drug information/9622.html" rel="external">methacholine</a> provocation concentration of 4 mg/mL or less) affects approximately 25 percent of patients with COPD and is associated with more rapid decline in lung function and mortality [<a href="#rid6">6,41,42</a>]. Combined data from two large studies (5938 total participants) found that airway hyperresponsiveness was associated with greater respiratory mortality (HR 2.38; 95% CI, 1.38-4.11) and greater decline in FEV<sub>1</sub> (12 to 13 mL/year) compared with absence of airway hyperresponsiveness [<a href="#rid41">41</a>]. </p><p>Histamine-induced airway hyperresponsiveness is also a predictor of greater mortality [<a href="#rid6">6</a>]. However, it is uncertain whether bronchodilator reversibility following inhaled short-acting beta-agonist (eg, <a class="drug drug_general" data-topicid="9396" href="/d/drug information/9396.html" rel="external">albuterol</a>) predicts mortality.</p><p class="headingAnchor" id="H200428268"><span class="h2">Types of COPD</span><span class="headingEndMark"> — </span>Only a few studies have focused on prognosis of specific types of COPD (such as emphysema) or severity of airflow limitation. In one study of 609 patients with severe emphysema (mean FEV<sub>1</sub> 27 percent of predicted), the following factors predicted mortality: advanced age (≥70 years), supplemental oxygen use, total lung capacity (&lt;140 percent of predicted), residual volume (≥262 percent of predicted), maximal workload during cardiopulmonary exercise testing (≤25 W for females, ≤40 W for males), BODE index (≥7), and increased emphysema in the lower lung zones and/or greater blood flow to the lower relative to the upper lung zones [<a href="#rid43">43</a>]. A separate study demonstrated that presence and severity of centrilobular emphysema, but not paraseptal emphysema, are associated with lung function decline and mortality in patients with COPD [<a href="#rid44">44</a>]. (See  <a class="medical medical_review" href="/d/html/1455.html" rel="external">"Chronic obstructive pulmonary disease: Diagnosis and staging", section on 'Definitions'</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">Acute exacerbations</span><span class="headingEndMark"> — </span>Compared with patients who do not have acute exacerbations, patients with COPD exacerbations are at increased risk for mortality and respiratory death. In one study with mean four-year follow-up, patients with exacerbations requiring medical therapy over a three-year baseline period had increased adjusted risk of overall mortality (hazard ratio 1.6, 95% CI 1.4-1.8 in the first year and 1.15, 95% CI 1.1-1.2 thereafter) [<a href="#rid45">45</a>]. Patients with exacerbations were also more likely to die of respiratory causes (40 versus 29 percent) compared with non-exacerbators, who were more likely to die of malignancies or cardiovascular disease during follow-up.</p><p>Patients with exacerbations severe enough to require hospitalization are also likely at higher risk for subsequent mortality, but estimates of risk vary widely [<a href="#rid46">46-53</a>].</p><p>In a study of 1016 patients hospitalized with a COPD exacerbation complicated by hypercapnia (PaCO<sub>2</sub> &gt;50 mmHg at admission), the in-hospital, 60-day, 90-day, one-year, and two-year mortality rates were 11, 20, 33, 43, and 49 percent, respectively [<a href="#rid48">48</a>]. Patient characteristics associated with death at six months included:</p><p class="bulletIndent1"><span class="glyph">●</span>Chronic health status</p><p class="bulletIndent1"><span class="glyph">●</span>Nutritional status</p><p class="bulletIndent1"><span class="glyph">●</span>Coexisting cardiac disease</p><p class="bulletIndent1"><span class="glyph">●</span>Severity of the acute illness (determined by the Acute Physiologic And Chronic Health Evaluation [APACHE] score and the PaO<sub>2</sub>/FiO<sub>2</sub> ratio)</p><p></p><p>Interestingly, the presence of heart failure or cor pulmonale was associated with a longer survival time after adjustment for other variables. This may be the result of the relatively good response of these disorders to acute therapy.</p><p>Subsequent studies have identified additional factors associated with poor outcome after hospitalization for COPD exacerbation. Decreased levels of serum albumin [<a href="#rid46">46</a>], low BMI [<a href="#rid46">46</a>], advanced pulmonary disease [<a href="#rid52">52</a>], and nonrespiratory organ dysfunction [<a href="#rid52">52</a>] are predictive of long-term mortality. In contrast, advanced age [<a href="#rid52">52</a>], prolonged hospital length of stay before ICU admission [<a href="#rid52">52</a>], severe respiratory dysfunction [<a href="#rid52">52,53</a>], and severe nonrespiratory organ dysfunction are associated with in-hospital mortality [<a href="#rid52">52,53</a>].</p><p class="headingAnchor" id="H7"><span class="h2">Hypercapnia</span><span class="headingEndMark"> — </span>Hypercapnia induced by an acute exacerbation of COPD does not predict increased mortality compared to eucapnia. In a five-year observational study of 85 patients admitted to the hospital with a COPD exacerbation, survival was similar among eucapnic patients (33 percent) and acutely hypercapnic patients (28 percent) [<a href="#rid49">49</a>]. In contrast, patients with chronic hypercapnia had a decreased five-year survival (11 percent)  (<a class="graphic graphic_figure graphicRef58903" href="/d/graphic/58903.html" rel="external">figure 1</a>). All three groups had similar levels of pulmonary function, as measured by FEV<sub>1</sub> and FVC. Only 24 percent of the patients who became hypercapnic during the acute illness subsequently developed chronic hypercapnia.</p><p class="headingAnchor" id="H8"><span class="h2">Acute respiratory failure</span><span class="headingEndMark"> — </span>Acute respiratory failure due to a COPD exacerbation does not appear to be associated with diminished long-term survival [<a href="#rid50">50,52</a>]. In an observational study of 36 patients with acute respiratory failure due to an acute exacerbation of COPD, two-year survival was 72 percent [<a href="#rid50">50</a>]. Compared with controls with similar baseline pulmonary function, there was no difference in two-year mortality.</p><p>A common clinical question is whether recurrent episodes of acute respiratory failure and mechanical ventilation affect the prognosis of COPD. Unfortunately, few data exist to answer this question.</p><p>A retrospective cohort study of 74 patients with severe COPD (mean FEV<sub>1</sub> 0.74 L) complicated by acute respiratory failure and ICU admission found an in-hospital mortality of 20 percent [<a href="#rid53">53</a>]. In this population, the cumulative mortality at one, two, and three years was 48, 58, and 64 percent, respectively. The degree of hypercarbia and higher APACHE II scores were correlated with in-hospital mortality; however, clinical factors independently associated with long-term survival could not be identified.</p><p class="headingAnchor" id="H2138835904"><span class="h2">COVID-19 infection</span><span class="headingEndMark"> — </span>COPD increases the morbidity and mortality associated with coronavirus disease 2019 (COVID-19; caused by severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]) [<a href="#rid54">54-56</a>]. Vaccination for either influenza or SARS-CoV-2 is associated with a decreased risk of death for patients with COPD [<a href="#rid54">54,57</a>]. Vaccination for patients with COPD is discussed separately. (See  <a class="medical medical_review" href="/d/html/120326.html" rel="external">"Stable COPD: Overview of management", section on 'Advice related to COVID-19'</a> and  <a class="medical medical_review" href="/d/html/120326.html" rel="external">"Stable COPD: Overview of management", section on 'Vaccination'</a> and  <a class="medical medical_review" href="/d/html/129849.html" rel="external">"COVID-19: Vaccines"</a>.)</p><p class="headingAnchor" id="H1308082290"><span class="h2">C-reactive protein</span><span class="headingEndMark"> — </span>C-reactive protein (CRP) is an acute phase reactant that is a sensitive, but not specific predictor of inflammation. An elevated CRP has been associated with increased morbidity and mortality and declining pulmonary function in some studies of patients with COPD [<a href="#rid10">10,58</a>], but not others [<a href="#rid59">59,60</a>]. (See  <a class="medical medical_review" href="/d/html/7483.html" rel="external">"Acute phase reactants", section on 'C-reactive protein'</a>.)</p><p>In the European Prospective Investigation Into Cancer (EPIC)-Norfolk study, high-sensitivity CRP levels and spirometry were assessed in 18,110 participants at baseline, 4 years (spirometry only), and 13 years [<a href="#rid58">58</a>]. An elevated baseline CRP was associated with lower baseline FEV<sub>1</sub> and FVC. In addition, an increase in CRP over time correlated with a slightly greater rate of decline in FEV<sub>1</sub> and FVC multivariate analysis. However, the baseline CRP level was not predictive of the annual rate of change in FEV<sub>1</sub> or FVC. </p><p class="headingAnchor" id="H9"><span class="h1">COMORBID DISEASES</span><span class="headingEndMark"> — </span>COPD has been linked to a number of comorbid conditions [<a href="#rid1">1</a>], such as lung cancer, cardiovascular diseases [<a href="#rid61">61-66</a>], sleep-related breathing disorders, diabetes mellitus [<a href="#rid67">67,68</a>], kidney insufficiency [<a href="#rid69">69</a>], osteoporosis [<a href="#rid70">70-73</a>], gastroesophageal reflux disease, psychiatric illness (eg, depression and anxiety) [<a href="#rid74">74-82</a>], and cognitive dysfunction [<a href="#rid83">83-86</a>]. Proactive identification and treatment of comorbidities can potentially improve outcomes [<a href="#rid87">87</a>].</p><p class="headingAnchor" id="H895929857"><span class="h2">Lung cancer</span><span class="headingEndMark"> — </span>COPD is an independent risk factor for lung cancer, and increases the risk of lung cancer by 6 to 13-fold relative to individuals without COPD [<a href="#rid88">88</a>]. Lung cancer and COPD occur as comorbid diseases at a higher rate than would be expected if they were independently triggered [<a href="#rid89">89</a>]. The association of emphysema with lung cancer is stronger than the association of airflow limitation and lung cancer, although both contribute to increased risk [<a href="#rid1">1,90</a>]. (See  <a class="medical medical_review" href="/d/html/4640.html" rel="external">"Cigarette smoking and other possible risk factors for lung cancer"</a>.)</p><p>Lung cancer is the main cause of death among patients with COPD [<a href="#rid1">1</a>]. The most important intervention to reduce death from lung cancer is smoking cessation. (See  <a class="medical medical_review" href="/d/html/16634.html" rel="external">"Overview of smoking cessation management in adults"</a> and  <a class="medical medical_review" href="/d/html/16706.html" rel="external">"Benefits and consequences of smoking cessation"</a>.) </p><p>The role of low-dose computed tomography (LDCT) in screening for lung cancer is described separately. (See  <a class="medical medical_review" href="/d/html/7566.html" rel="external">"Screening for lung cancer"</a>.)</p><p class="headingAnchor" id="H3877646548"><span class="h2">Cardiovascular disease</span><span class="headingEndMark"> — </span>Cardiovascular diseases, such as coronary heart disease, heart failure, arrhythmias, peripheral vascular disease, and hypertension, are all increased in patients with COPD [<a href="#rid1">1,67</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Coronary heart disease</strong> – Major cardiovascular risk factors are often poorly monitored and undertreated in patients with COPD [<a href="#rid91">91</a>]. Patients with COPD have a two to five times higher risk of ischemic heart disease than the general population [<a href="#rid92">92</a>], so a high level of clinical suspicion is appropriate to avoid overlooking this common comorbid condition. </p><p></p><p class="bulletIndent1">For ambulatory patients with COPD and symptoms that could be attributable to myocardial ischemia, we typically perform a baseline electrocardiogram and <a class="drug drug_general" data-topicid="9380" href="/d/drug information/9380.html" rel="external">dobutamine</a> stress imaging, as exercise limitations may preclude exercise stress testing, and potential bronchoconstriction is often a contraindication to vasodilator radionuclide myocardial perfusion imaging. (See  <a class="medical medical_review" href="/d/html/1437.html" rel="external">"Management of the patient with COPD and cardiovascular disease", section on 'Myocardial ischemia'</a>.)</p><p></p><p class="bulletIndent1">For patients presenting to the hospital with a COPD exacerbation, screening measures generally include obtaining an electrocardiogram and measuring serum troponin [<a href="#rid87">87</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Heart failure</strong> – Patients with COPD are at risk for both heart failure with preserved ejection fraction (HFpEF) and with reduced ejection fraction (HFrEF) [<a href="#rid1">1</a>].Heart failure is an independent predictor of all-cause mortality in patients with COPD [<a href="#rid1">1</a>], with HFrEF demonstrating higher risk compared with HFpEF [<a href="#rid93">93</a>]. </p><p></p><p class="bulletIndent1">Heart failure can go unrecognized in stable ambulatory patients with COPD and can mimic or present concomitantly with COPD exacerbations [<a href="#rid94">94</a>]. Helpful tests in evaluating patients with suspected heart failure include N-terminal pro-brain natriuretic peptide (NT pro-BNP) measurement and echocardiography [<a href="#rid95">95,96</a>]. (See  <a class="medical medical_review" href="/d/html/1437.html" rel="external">"Management of the patient with COPD and cardiovascular disease", section on 'Heart failure'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Arrhythmias</strong> – Arrhythmias, particularly atrial fibrillation, are common in COPD [<a href="#rid1">1</a>]. The risk of atrial fibrillation increases as the forced expiratory volume in one second (FEV<sub>1</sub>) decreases. The occurrence of atrial and ventricular arrhythmias and their management in COPD are discussed separately. (See  <a class="medical medical_review" href="/d/html/1454.html" rel="external">"Arrhythmias in COPD"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Peripheral artery disease</strong> – Peripheral artery disease (PAD) is more prevalent in patients with COPD compared with non-COPD controls (9 percent versus 2 percent) [<a href="#rid1">1,97</a>]. Comorbid PAD can further impair exercise tolerance. (See  <a class="medical medical_review" href="/d/html/8208.html" rel="external">"Clinical features and diagnosis of lower extremity peripheral artery disease"</a>.)</p><p></p><p class="bulletIndent1">Focused questions about lower extremity discomfort that might be indicative of PAD and assessment of pedal pulses can help identify PAD. Concerning features should be further evaluated with measurement of ankle-brachial index (ABI). (See  <a class="medical medical_review" href="/d/html/8208.html" rel="external">"Clinical features and diagnosis of lower extremity peripheral artery disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypertension</strong> – Hypertension is a common comorbidity of COPD and can contribute to development of diastolic ventricular dysfunction and coronary heart disease [<a href="#rid1">1,98</a>]. Hypertension, when present, should be treated according to the usual guidelines with a goal of optimal blood pressure control [<a href="#rid1">1</a>]. Furthermore, COPD does not need to be treated differently in patients with hypertension. (See  <a class="medical medical_review" href="/d/html/3852.html" rel="external">"Overview of hypertension in adults"</a>.)</p><p></p><p class="headingAnchor" id="H3362836199"><span class="h2">Sleep-disordered breathing disorders</span><span class="headingEndMark"> — </span>Sleep-related breathing disorders (SRBD), including sleep-related hypoxemia, obstructive sleep apnea, central sleep apnea, respiratory effort-related arousals (RERAs), and sleep-related hypoventilation, are present in approximately 40 percent of patients with COPD [<a href="#rid99">99</a>]. Moderate-to-severe obstructive sleep apnea (OSA) is present in 10 to 30 percent of patients with COPD, similar to the prevalence in the general population. However, the combination of OSA and COPD leads to a worse prognosis compared with either COPD or OSA alone [<a href="#rid1">1</a>]. </p><p>As SRBD is often unreported by patients with COPD, it is prudent to obtain a specific sleep history  (<a class="graphic graphic_table graphicRef55633" href="/d/graphic/55633.html" rel="external">table 2</a>). The evaluation and management of SRBD in COPD are discussed separately. (See  <a class="medical medical_review" href="/d/html/7680.html" rel="external">"Sleep-related breathing disorders in COPD"</a>.)</p><p class="headingAnchor" id="H3674746751"><span class="h2">Metabolic syndrome and diabetes mellitus</span><span class="headingEndMark"> — </span>Metabolic syndrome is estimated to be present in 30 percent of patients with COPD [<a href="#rid100">100</a>]. The prevalence of diabetes is greater among patients with COPD than in a non-COPD control population (OR 1.22, 95% CI 1.07-1.38) based on a systematic review [<a href="#rid101">101</a>]; a separate review reported similar results [<a href="#rid92">92</a>]. </p><p>Comorbid diabetes is associated with a higher risk of hospitalization and mortality [<a href="#rid102">102</a>]. For patients with COPD and diabetes who are active cigarette smokers, smoking cessation is essential to improving long-term outcomes. (See  <a class="medical medical_review" href="/d/html/1750.html" rel="external">"Overview of general medical care in nonpregnant adults with diabetes mellitus", section on 'Smoking cessation'</a>.)</p><p>The initial evaluation and diagnosis of metabolic syndrome and diabetes mellitus are discussed separately. (See  <a class="medical medical_review" href="/d/html/1784.html" rel="external">"Metabolic syndrome (insulin resistance syndrome or syndrome X)"</a> and  <a class="medical medical_review" href="/d/html/1812.html" rel="external">"Clinical presentation, diagnosis, and initial evaluation of diabetes mellitus in adults"</a>.)</p><p class="headingAnchor" id="H4193694398"><span class="h2">Osteoporosis</span><span class="headingEndMark"> — </span>Osteopenia, osteoporosis, and osteoporotic fractures (especially vertebral) are common in COPD patients [<a href="#rid1">1</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span>A systematic review and meta-analysis that included 58 studies (8753 participants with COPD) found a prevalence of osteoporosis of 38 percent (95% CI 34-43) [<a href="#rid73">73</a>]. Risk factors for osteoporosis were body mass index (BMI) &lt;18.5 kg/m<sup>2</sup> (OR 4.26) and sarcopenia (OR 3.65), while a lower FEV<sub>1</sub> was not.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a separate study of vertebral bone mineral density (vBMD) in 3321 current and ex-smokers, low vBMD was noted in 58 percent overall and in 84 percent of participants with very severe COPD [<a href="#rid72">72</a>]. Vertebral fractures were present in 37 percent and were associated with lower vBMD. </p><p></p><p>Smoking, reduced physical activity, low body weight, and low vitamin D can all contribute to development of osteoporosis. Identifying low bone mineral density and initiating treatment can help prevent fractures. Guidelines for screening for osteoporosis are reviewed separately. (See  <a class="medical medical_review" href="/d/html/2046.html" rel="external">"Screening for osteoporosis in postmenopausal women and men"</a>.)</p><p>Use of oral glucocorticoids (and possibly inhaled high-dose glucocorticoids) can increase the risk of osteoporotic fracture. Steps to reduce glucocorticoid-induced bone loss are discussed separately. (See  <a class="medical medical_review" href="/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids", section on 'Bone and muscle effects'</a> and  <a class="medical medical_review" href="/d/html/540.html" rel="external">"Major side effects of inhaled glucocorticoids", section on 'Osteoporosis and fracture risk in adults'</a> and  <a class="medical medical_review" href="/d/html/2034.html" rel="external">"Prevention and treatment of glucocorticoid-induced osteoporosis"</a>.)</p><p class="headingAnchor" id="H4016545535"><span class="h2">Renal insufficiency</span><span class="headingEndMark"> — </span>A potential association between COPD and renal insufficiency is suggested by observational data [<a href="#rid69">69,103</a>]. In a series of 356 older adults (mean age 75.4 years) with COPD, renal insufficiency (glomerular filtration rate [GFR] &lt;60 mL/min/1.73 m<sup>2</sup>) was detected in 43 percent, compared with 23 percent of older adults without COPD [<a href="#rid69">69</a>]. In addition, approximately half of the patients with COPD and a reduced GFR had a normal serum creatinine. This latter group of patients with "covert" renal insufficiency was more likely to have a low serum albumin and low muscle mass.</p><p class="headingAnchor" id="H3358444750"><span class="h2">Gastroesophageal reflux disease</span><span class="headingEndMark"> — </span>Estimates of the prevalence of gastroesophageal reflux disease (GERD) in patients with COPD vary widely (19 to 78 percent), but are generally higher than estimates of GERD in otherwise healthy control patients (18 percent) [<a href="#rid104">104,105</a>]. GERD may contribute to COPD exacerbations, although the mechanism is unclear [<a href="#rid1">1,106</a>]. Lacking data to suggest otherwise, recommendations for the diagnosis and treatment of GERD follow those for the general population. (See  <a class="medical medical_review" href="/d/html/2265.html" rel="external">"Clinical manifestations and diagnosis of gastroesophageal reflux in adults"</a> and  <a class="medical medical_review" href="/d/html/2258.html" rel="external">"Medical management of gastroesophageal reflux disease in adults"</a>.)</p><p class="headingAnchor" id="H3031281331"><span class="h2">Depression and anxiety</span><span class="headingEndMark"> — </span>Patients with COPD have a higher risk of depression and anxiety than smokers without COPD or nonsmokers [<a href="#rid1">1,79,107</a>]. A three-year observational study, the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study, examined the prevalence of depression among 2118 subjects with COPD, 335 smokers without COPD, and 243 nonsmokers [<a href="#rid79">79</a>]. Depression was more prevalent among subjects with COPD (26 percent), than smokers without COPD (12 percent) or nonsmokers (7 percent) and was associated with worse health and functional status. </p><p>Additional studies are needed to determine the optimal methods for the diagnosis [<a href="#rid80">80,81</a>] and treatment of depression in patients with COPD. Comprehensive pulmonary rehabilitation programs appear helpful in reducing depression and anxiety [<a href="#rid108">108</a>]. Pulmonary rehabilitation and the diagnosis and management of depression and anxiety are reviewed separately. (See  <a class="medical medical_review" href="/d/html/1463.html" rel="external">"Pulmonary rehabilitation", section on 'Psychological support'</a> and  <a class="medical medical_review" href="/d/html/83887.html" rel="external">"Screening for depression in adults"</a> and  <a class="medical medical_review" href="/d/html/1725.html" rel="external">"Unipolar major depression in adults: Choosing initial treatment"</a> and  <a class="medical medical_review" href="/d/html/14687.html" rel="external">"Unipolar depression in adults: Supportive psychotherapy"</a> and  <a class="medical medical_review" href="/d/html/496.html" rel="external">"Generalized anxiety disorder in adults: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/101879.html" rel="external">"Generalized anxiety disorder in adults: Management"</a>.)</p><p class="headingAnchor" id="H1766273720"><span class="h2">Cognition impairment</span><span class="headingEndMark"> — </span>Several studies have reported cognitive dysfunction in patients with COPD, predominantly in severe COPD [<a href="#rid83">83,109-111</a>]. In a survey of 4150 older adults, the adjusted mean cognition scores of those with severe COPD were significantly lower than those with nonsevere or absent COPD [<a href="#rid83">83</a>]. (See  <a class="medical medical_review" href="/d/html/5081.html" rel="external">"Mild cognitive impairment: Epidemiology, pathology, and clinical assessment"</a>.)</p><p class="headingAnchor" id="H10"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15430.html" rel="external">"Patient education: Chronic obstructive pulmonary disease (COPD) (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/4649.html" rel="external">"Patient education: Chronic obstructive pulmonary disease (COPD) (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H11"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>The natural history and prognosis of COPD are variable and factors influencing this variability are incompletely understood. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Factors, such as genetic predisposition, severity of disease, environmental exposures, comorbidities, and, to a lesser degree, acute exacerbations appear to influence prognosis. (See <a class="local">'Prognostic factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Short-term (ie, in-hospital) survival for patients with COPD and respiratory failure is determined by the overall severity of acute illness, rather than the degree of respiratory failure. In comparison, long-term survival is primarily influenced by the severity of COPD and the presence of comorbid conditions. (See <a class="local">'Acute exacerbations'</a> above and <a class="local">'Acute respiratory failure'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>COPD is associated with a number of comorbid conditions, such as lung cancer, cardiovascular diseases, sleep-disordered breathing, diabetes mellitus, renal insufficiency, osteoporosis, psychiatric illness (eg, depression and anxiety), and cognitive dysfunction. (See <a class="local">'Comorbid diseases'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Lung cancer is the main cause of death among patients with COPD. To reduce mortality from lung cancer, all patients with COPD should be strongly encouraged to stop smoking and patients who meet criteria for screening should be offered the choice of low-dose computed tomography (LDCT). (See <a class="local">'Lung cancer'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cardiovascular diseases, such as coronary heart disease, heart failure, peripheral artery disease, and hypertension, are common comorbidities of COPD. A high index of suspicion and appropriate testing should be employed to avoid overlooking opportunities for directed treatment. (See <a class="local">'Cardiovascular disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Sleep-related breathing disorders (SRBD) are common in COPD and can contribute to poor quality of life and increased morbidity and mortality. As SRBD may be unreported by patients, a specific sleep history should be obtained  (<a class="graphic graphic_table graphicRef55633" href="/d/graphic/55633.html" rel="external">table 2</a>) and followed by a formal sleep evaluation as indicated. (See <a class="local">'Sleep-disordered breathing disorders'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Metabolic syndrome, diabetes mellitus, and renal insufficiency are increased among patients with COPD. (See <a class="local">'Metabolic syndrome and diabetes mellitus'</a> above and <a class="local">'Renal insufficiency'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with COPD have a higher risk of depression and anxiety than smokers without COPD or nonsmokers. Pulmonary rehabilitation can help reduce depression and anxiety. (See <a class="local">'Depression and anxiety'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management , and prevention of chronic obstructive pulmonary disease (2018 Report). https://goldcopd.org/ (Accessed on October 28, 2018).</li><li><a class="nounderline abstract_t">Ford ES. Trends in mortality from COPD among adults in the United States. Chest 2015; 148:962.</a></li><li class="breakAll">Centers for Disease Control and Prevention. COPD death rates in the United States. https://www.cdc.gov/copd/data.html (Accessed on October 28, 2018).</li><li><a class="nounderline abstract_t">Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350:1005.</a></li><li><a class="nounderline abstract_t">Heffner JE, Mularski RA, Calverley PM. COPD performance measures: missing opportunities for improving care. Chest 2010; 137:1181.</a></li><li><a class="nounderline abstract_t">Hospers JJ, Postma DS, Rijcken B, et al. Histamine airway hyper-responsiveness and mortality from chronic obstructive pulmonary disease: a cohort study. Lancet 2000; 356:1313.</a></li><li><a class="nounderline abstract_t">Diaz PT, King MA, Pacht ER, et al. Increased susceptibility to pulmonary emphysema among HIV-seropositive smokers. Ann Intern Med 2000; 132:369.</a></li><li><a class="nounderline abstract_t">Wilkinson TM, Patel IS, Wilks M, et al. Airway bacterial load and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003; 167:1090.</a></li><li><a class="nounderline abstract_t">Berry MJ, Adair NE, Rejeski WJ. Use of peak oxygen consumption in predicting physical function and quality of life in COPD patients. Chest 2006; 129:1516.</a></li><li><a class="nounderline abstract_t">Dahl M, Vestbo J, Lange P, et al. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175:250.</a></li><li><a class="nounderline abstract_t">Drummond MB, Blackford AL, Benditt JO, et al. Continuous oxygen use in nonhypoxemic emphysema patients identifies a high-risk subset of patients: retrospective analysis of the National Emphysema Treatment Trial. Chest 2008; 134:497.</a></li><li><a class="nounderline abstract_t">de Torres JP, Cote CG, López MV, et al. Sex differences in mortality in patients with COPD. Eur Respir J 2009; 33:528.</a></li><li><a class="nounderline abstract_t">Kohansal R, Martinez-Camblor P, Agustí A, et al. The natural history of chronic airflow obstruction revisited: an analysis of the Framingham offspring cohort. Am J Respir Crit Care Med 2009; 180:3.</a></li><li><a class="nounderline abstract_t">Haruna A, Muro S, Nakano Y, et al. CT scan findings of emphysema predict mortality in COPD. Chest 2010; 138:635.</a></li><li><a class="nounderline abstract_t">Oh AS, Baraghoshi D, Lynch DA, et al. Emphysema Progression at CT by Deep Learning Predicts Functional Impairment and Mortality: Results from the COPDGene Study. Radiology 2022; 304:672.</a></li><li><a class="nounderline abstract_t">Martínez-García MÁ, Faner R, Oscullo G, et al. Chronic Bronchial Infection Is Associated with More Rapid Lung Function Decline in Chronic Obstructive Pulmonary Disease. Ann Am Thorac Soc 2022; 19:1842.</a></li><li><a class="nounderline abstract_t">Balasubramanian A, Putcha N, MacIntyre NR, et al. Diffusing Capacity and Mortality in Chronic Obstructive Pulmonary Disease. Ann Am Thorac Soc 2023; 20:38.</a></li><li><a class="nounderline abstract_t">Labaki WW, Gu T, Murray S, et al. Causes of and Clinical Features Associated with Death in Tobacco Cigarette Users by Lung Function Impairment. Am J Respir Crit Care Med 2023; 208:451.</a></li><li><a class="nounderline abstract_t">Traver GA, Cline MG, Burrows B. Predictors of mortality in chronic obstructive pulmonary disease. A 15-year follow-up study. Am Rev Respir Dis 1979; 119:895.</a></li><li><a class="nounderline abstract_t">Vestbo J, Edwards LD, Scanlon PD, et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med 2011; 365:1184.</a></li><li><a class="nounderline abstract_t">Drummond MB, Hansel NN, Connett JE, et al. Spirometric predictors of lung function decline and mortality in early chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 185:1301.</a></li><li><a class="nounderline abstract_t">Miniati M, Monti S, Pavlickova I, Bottai M. Survival in COPD: impact of lung dysfunction and comorbidities. Medicine (Baltimore) 2014; 93:e76.</a></li><li><a class="nounderline abstract_t">Lange P, Celli B, Agustí A, et al. Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease. N Engl J Med 2015; 373:111.</a></li><li><a class="nounderline abstract_t">Casanova C, de Torres JP, Aguirre-Jaíme A, et al. The progression of chronic obstructive pulmonary disease is heterogeneous: the experience of the BODE cohort. Am J Respir Crit Care Med 2011; 184:1015.</a></li><li><a class="nounderline abstract_t">Nishimura M, Makita H, Nagai K, et al. Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 185:44.</a></li><li><a class="nounderline abstract_t">Ong KC, Earnest A, Lu SJ. A multidimensional grading system (BODE index) as predictor of hospitalization for COPD. Chest 2005; 128:3810.</a></li><li><a class="nounderline abstract_t">Martinez FJ, Han MK, Andrei AC, et al. Longitudinal change in the BODE index predicts mortality in severe emphysema. Am J Respir Crit Care Med 2008; 178:491.</a></li><li><a class="nounderline abstract_t">Wilson DO, Rogers RM, Wright EC, Anthonisen NR. Body weight in chronic obstructive pulmonary disease. The National Institutes of Health Intermittent Positive-Pressure Breathing Trial. Am Rev Respir Dis 1989; 139:1435.</a></li><li><a class="nounderline abstract_t">Gray-Donald K, Gibbons L, Shapiro SH, et al. Nutritional status and mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996; 153:961.</a></li><li><a class="nounderline abstract_t">Schols AM, Slangen J, Volovics L, Wouters EF. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157:1791.</a></li><li><a class="nounderline abstract_t">Landbo C, Prescott E, Lange P, et al. Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160:1856.</a></li><li><a class="nounderline abstract_t">Prescott E, Almdal T, Mikkelsen KL, et al. Prognostic value of weight change in chronic obstructive pulmonary disease: results from the Copenhagen City Heart Study. Eur Respir J 2002; 20:539.</a></li><li><a class="nounderline abstract_t">Vestbo J, Prescott E, Almdal T, et al. Body mass, fat-free body mass, and prognosis in patients with chronic obstructive pulmonary disease from a random population sample: findings from the Copenhagen City Heart Study. Am J Respir Crit Care Med 2006; 173:79.</a></li><li><a class="nounderline abstract_t">Ischaki E, Papatheodorou G, Gaki E, et al. Body mass and fat-free mass indices in COPD: relation with variables expressing disease severity. Chest 2007; 132:164.</a></li><li><a class="nounderline abstract_t">Machado FVC, Vogelmeier CF, Jörres RA, et al. Differential Impact of Low Fat-Free Mass in People With COPD Based on BMI Classifications: Results From the COPD and Systemic Consequences-Comorbidities Network. Chest 2023; 163:1071.</a></li><li><a class="nounderline abstract_t">Boucher RC. Muco-Obstructive Lung Diseases. N Engl J Med 2019; 380:1941.</a></li><li><a class="nounderline abstract_t">Dunican EM, Elicker BM, Henry T, et al. Mucus Plugs and Emphysema in the Pathophysiology of Airflow Obstruction and Hypoxemia in Smokers. Am J Respir Crit Care Med 2021; 203:957.</a></li><li><a class="nounderline abstract_t">Okajima Y, Come CE, Nardelli P, et al. Luminal Plugging on Chest CT Scan: Association With Lung Function, Quality of Life, and COPD Clinical Phenotypes. Chest 2020; 158:121.</a></li><li><a class="nounderline abstract_t">Hogg JC, Chu FS, Tan WC, et al. Survival after lung volume reduction in chronic obstructive pulmonary disease: insights from small airway pathology. Am J Respir Crit Care Med 2007; 176:454.</a></li><li><a class="nounderline abstract_t">Diaz AA, Orejas JL, Grumley S, et al. Airway-Occluding Mucus Plugs and Mortality in Patients With Chronic Obstructive Pulmonary Disease. JAMA 2023; 329:1832.</a></li><li><a class="nounderline abstract_t">Tkacova R, Dai DLY, Vonk JM, et al. Airway hyperresponsiveness in chronic obstructive pulmonary disease: A marker of asthma-chronic obstructive pulmonary disease overlap syndrome? J Allergy Clin Immunol 2016; 138:1571.</a></li><li><a class="nounderline abstract_t">Tashkin DP, Altose MD, Connett JE, et al. Methacholine reactivity predicts changes in lung function over time in smokers with early chronic obstructive pulmonary disease. The Lung Health Study Research Group. Am J Respir Crit Care Med 1996; 153:1802.</a></li><li><a class="nounderline abstract_t">Martinez FJ, Foster G, Curtis JL, et al. Predictors of mortality in patients with emphysema and severe airflow obstruction. Am J Respir Crit Care Med 2006; 173:1326.</a></li><li><a class="nounderline abstract_t">Shiraishi Y, Tanabe N, Shimizu K, et al. Stronger Associations of Centrilobular Than Paraseptal Emphysema With Longitudinal Changes in Diffusing Capacity and Mortality in COPD. Chest 2023; 164:327.</a></li><li><a class="nounderline abstract_t">Lenoir A, Whittaker H, Gayle A, et al. Mortality in non-exacerbating COPD: a longitudinal analysis of UK primary care data. Thorax 2023; 78:904.</a></li><li><a class="nounderline abstract_t">Gunen H, Hacievliyagil SS, Kosar F, et al. Factors affecting survival of hospitalised patients with COPD. Eur Respir J 2005; 26:234.</a></li><li><a class="nounderline abstract_t">Patil SP, Krishnan JA, Lechtzin N, Diette GB. In-hospital mortality following acute exacerbations of chronic obstructive pulmonary disease. Arch Intern Med 2003; 163:1180.</a></li><li><a class="nounderline abstract_t">Connors AF Jr, Dawson NV, Thomas C, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med 1996; 154:959.</a></li><li><a class="nounderline abstract_t">Costello R, Deegan P, Fitzpatrick M, McNicholas WT. Reversible hypercapnia in chronic obstructive pulmonary disease: a distinct pattern of respiratory failure with a favorable prognosis. Am J Med 1997; 102:239.</a></li><li><a class="nounderline abstract_t">Martin TR, Lewis SW, Albert RK. The prognosis of patients with chronic obstructive pulmonary disease after hospitalization for acute respiratory failure. Chest 1982; 82:310.</a></li><li><a class="nounderline abstract_t">Hudson LD. Survival data in patients with acute and chronic lung disease requiring mechanical ventilation. Am Rev Respir Dis 1989; 140:S19.</a></li><li><a class="nounderline abstract_t">Seneff MG, Wagner DP, Wagner RP, et al. Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease. JAMA 1995; 274:1852.</a></li><li><a class="nounderline abstract_t">Breen D, Churches T, Hawker F, Torzillo PJ. Acute respiratory failure secondary to chronic obstructive pulmonary disease treated in the intensive care unit: a long term follow up study. Thorax 2002; 57:29.</a></li><li><a class="nounderline abstract_t">Hippisley-Cox J, Coupland CA, Mehta N, et al. Risk prediction of covid-19 related death and hospital admission in adults after covid-19 vaccination: national prospective cohort study. BMJ 2021; 374:n2244.</a></li><li><a class="nounderline abstract_t">Puebla Neira DA, Watts A, Seashore J, et al. Outcomes of Patients with COPD Hospitalized for Coronavirus Disease 2019. Chronic Obstr Pulm Dis 2021; 8:517.</a></li><li><a class="nounderline abstract_t">Gerayeli FV, Milne S, Cheung C, et al. COPD and the risk of poor outcomes in COVID-19: A systematic review and meta-analysis. EClinicalMedicine 2021; 33:100789.</a></li><li><a class="nounderline abstract_t">Conlon A, Ashur C, Washer L, et al. Impact of the influenza vaccine on COVID-19 infection rates and severity. Am J Infect Control 2021; 49:694.</a></li><li><a class="nounderline abstract_t">Ahmadi-Abhari S, Kaptoge S, Luben RN, et al. Longitudinal association of C-reactive protein and lung function over 13 years: The EPIC-Norfolk study. Am J Epidemiol 2014; 179:48.</a></li><li><a class="nounderline abstract_t">de Torres JP, Pinto-Plata V, Casanova C, et al. C-reactive protein levels and survival in patients with moderate to very severe COPD. Chest 2008; 133:1336.</a></li><li><a class="nounderline abstract_t">Stolz D, Christ-Crain M, Morgenthaler NG, et al. Copeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD. Chest 2007; 131:1058.</a></li><li><a class="nounderline abstract_t">Barr RG, Bluemke DA, Ahmed FS, et al. Percent emphysema, airflow obstruction, and impaired left ventricular filling. N Engl J Med 2010; 362:217.</a></li><li><a class="nounderline abstract_t">Watz H, Waschki B, Meyer T, et al. Decreasing cardiac chamber sizes and associated heart dysfunction in COPD: role of hyperinflation. Chest 2010; 138:32.</a></li><li><a class="nounderline abstract_t">Williams MC, Murchison JT, Edwards LD, et al. Coronary artery calcification is increased in patients with COPD and associated with increased morbidity and mortality. Thorax 2014; 69:718.</a></li><li><a class="nounderline abstract_t">Portegies ML, Lahousse L, Joos GF, et al. Chronic Obstructive Pulmonary Disease and the Risk of Stroke. The Rotterdam Study. Am J Respir Crit Care Med 2016; 193:251.</a></li><li><a class="nounderline abstract_t">Takagi H, Umemoto T, ALICE (All-Literature Investigation of Cardiovascular Evidence) Group. A Meta-Analysis of the Association of Chronic Obstructive Pulmonary Disease with Abdominal Aortic Aneurysm Presence. Ann Vasc Surg 2016; 34:84.</a></li><li><a class="nounderline abstract_t">Rothnie KJ, Connell O, Müllerová H, et al. Myocardial Infarction and Ischemic Stroke after Exacerbations of Chronic Obstructive Pulmonary Disease. Ann Am Thorac Soc 2018; 15:935.</a></li><li><a class="nounderline abstract_t">Feary JR, Rodrigues LC, Smith CJ, et al. Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. Thorax 2010; 65:956.</a></li><li><a class="nounderline abstract_t">Meteran H, Backer V, Kyvik KO, et al. Comorbidity between chronic obstructive pulmonary disease and type 2 diabetes: A nation-wide cohort twin study. Respir Med 2015; 109:1026.</a></li><li><a class="nounderline abstract_t">Incalzi RA, Corsonello A, Pedone C, et al. Chronic renal failure: a neglected comorbidity of COPD. Chest 2010; 137:831.</a></li><li><a class="nounderline abstract_t">Ferguson GT, Calverley PMA, Anderson JA, et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest 2009; 136:1456.</a></li><li><a class="nounderline abstract_t">Bon J, Fuhrman CR, Weissfeld JL, et al. Radiographic emphysema predicts low bone mineral density in a tobacco-exposed cohort. Am J Respir Crit Care Med 2011; 183:885.</a></li><li><a class="nounderline abstract_t">Jaramillo JD, Wilson C, Stinson DS, et al. Reduced Bone Density and Vertebral Fractures in Smokers. Men and COPD Patients at Increased Risk. Ann Am Thorac Soc 2015; 12:648.</a></li><li><a class="nounderline abstract_t">Chen YW, Ramsook AH, Coxson HO, et al. Prevalence and Risk Factors for Osteoporosis in Individuals With COPD: A Systematic Review and Meta-analysis. Chest 2019; 156:1092.</a></li><li><a class="nounderline abstract_t">Light RW, Merrill EJ, Despars JA, et al. Prevalence of depression and anxiety in patients with COPD. Relationship to functional capacity. Chest 1985; 87:35.</a></li><li><a class="nounderline abstract_t">Omachi TA, Katz PP, Yelin EH, et al. Depression and health-related quality of life in chronic obstructive pulmonary disease. Am J Med 2009; 122:778.e9.</a></li><li><a class="nounderline abstract_t">Schneider C, Jick SS, Bothner U, Meier CR. COPD and the risk of depression. Chest 2010; 137:341.</a></li><li><a class="nounderline abstract_t">Katz PP, Julian LJ, Omachi TA, et al. The impact of disability on depression among individuals with COPD. Chest 2010; 137:838.</a></li><li><a class="nounderline abstract_t">Kim KU, Park HK, Jung HY, et al. Association of depression with disease severity in patients with chronic obstructive pulmonary disease. Lung 2014; 192:243.</a></li><li><a class="nounderline abstract_t">Hanania NA, Müllerova H, Locantore NW, et al. Determinants of depression in the ECLIPSE chronic obstructive pulmonary disease cohort. Am J Respir Crit Care Med 2011; 183:604.</a></li><li><a class="nounderline abstract_t">Arimura Y, Yamazaki S, Yanagi S, et al. Clinical usefulness of the two-question assessment tool for depressive symptoms in Japanese patients with chronic obstructive pulmonary disease. Lung 2013; 191:101.</a></li><li><a class="nounderline abstract_t">Julian LJ, Gregorich SE, Earnest G, et al. Screening for depression in chronic obstructive pulmonary disease. COPD 2009; 6:452.</a></li><li><a class="nounderline abstract_t">Montserrat-Capdevila J, Godoy P, Marsal JR, et al. Overview of the Impact of Depression and Anxiety in Chronic Obstructive Pulmonary Disease. Lung 2017; 195:77.</a></li><li><a class="nounderline abstract_t">Hung WW, Wisnivesky JP, Siu AL, Ross JS. Cognitive decline among patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180:134.</a></li><li><a class="nounderline abstract_t">Singh B, Parsaik AK, Mielke MM, et al. Chronic obstructive pulmonary disease and association with mild cognitive impairment: the Mayo Clinic Study of Aging. Mayo Clin Proc 2013; 88:1222.</a></li><li><a class="nounderline abstract_t">Singh B, Mielke MM, Parsaik AK, et al. A prospective study of chronic obstructive pulmonary disease and the risk for mild cognitive impairment. JAMA Neurol 2014; 71:581.</a></li><li><a class="nounderline abstract_t">Martinez CH, Richardson CR, Han MK, Cigolle CT. Chronic obstructive pulmonary disease, cognitive impairment, and development of disability: the health and retirement study. Ann Am Thorac Soc 2014; 11:1362.</a></li><li><a class="nounderline abstract_t">Vespasiani-Gentilucci U, Pedone C, Muley-Vilamu M, Antonelli-Incalzi R. The pharmacological treatment of chronic comorbidities in COPD: mind the gap! Pulm Pharmacol Ther 2018; 51:48.</a></li><li><a class="nounderline abstract_t">Hopkins RJ, Duan F, Chiles C, et al. Reduced Expiratory Flow Rate among Heavy Smokers Increases Lung Cancer Risk. Results from the National Lung Screening Trial-American College of Radiology Imaging Network Cohort. Ann Am Thorac Soc 2017; 14:392.</a></li><li><a class="nounderline abstract_t">Durham AL, Adcock IM. The relationship between COPD and lung cancer. Lung Cancer 2015; 90:121.</a></li><li><a class="nounderline abstract_t">de-Torres JP, Wilson DO, Sanchez-Salcedo P, et al. Lung cancer in patients with chronic obstructive pulmonary disease. Development and validation of the COPD Lung Cancer Screening Score. Am J Respir Crit Care Med 2015; 191:285.</a></li><li><a class="nounderline abstract_t">Hawkins NM, Peterson S, Ezzat AM, et al. Control of Cardiovascular Risk Factors in Patients with Chronic Obstructive Pulmonary Disease. Ann Am Thorac Soc 2022; 19:1102.</a></li><li><a class="nounderline abstract_t">Chen W, Thomas J, Sadatsafavi M, FitzGerald JM. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med 2015; 3:631.</a></li><li><a class="nounderline abstract_t">Gulea C, Zakeri R, Quint JK. Differences in Outcomes between Heart Failure Phenotypes in Patients with Coexistent Chronic Obstructive Pulmonary Disease: A Cohort Study. Ann Am Thorac Soc 2022; 19:971.</a></li><li><a class="nounderline abstract_t">Rutten FH, Cramer MJ, Grobbee DE, et al. Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. Eur Heart J 2005; 26:1887.</a></li><li><a class="nounderline abstract_t">Abroug F, Ouanes-Besbes L. Detection of acute heart failure in chronic obstructive pulmonary disease patients: role of B-type natriuretic peptide. Curr Opin Crit Care 2008; 14:340.</a></li><li><a class="nounderline abstract_t">MacDonald MI, Shafuddin E, King PT, et al. Cardiac dysfunction during exacerbations of chronic obstructive pulmonary disease. Lancet Respir Med 2016; 4:138.</a></li><li><a class="nounderline abstract_t">Houben-Wilke S, Jörres RA, Bals R, et al. Peripheral Artery Disease and Its Clinical Relevance in Patients with Chronic Obstructive Pulmonary Disease in the COPD and Systemic Consequences-Comorbidities Network Study. Am J Respir Crit Care Med 2017; 195:189.</a></li><li><a class="nounderline abstract_t">Divo M, Cote C, de Torres JP, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 186:155.</a></li><li><a class="nounderline abstract_t">Chen R, Tian JW, Zhou LQ, et al. The relationship between sleep quality and functional exercise capacity in COPD. Clin Respir J 2016; 10:477.</a></li><li><a class="nounderline abstract_t">Cebron Lipovec N, Beijers RJ, van den Borst B, et al. The Prevalence of Metabolic Syndrome In Chronic Obstructive Pulmonary Disease: A Systematic Review. COPD 2016; 13:399.</a></li><li><a class="nounderline abstract_t">Yin HL, Yin SQ, Lin QY, et al. Prevalence of comorbidities in chronic obstructive pulmonary disease patients: A meta-analysis. Medicine (Baltimore) 2017; 96:e6836.</a></li><li><a class="nounderline abstract_t">Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 2008; 32:962.</a></li><li><a class="nounderline abstract_t">AbdelHalim HA, AboElNaga HH. Is Renal Impairment an Anticipated COPD Comorbidity? Respir Care 2016; 61:1201.</a></li><li><a class="nounderline abstract_t">Broers C, Tack J, Pauwels A. Review article: gastro-oesophageal reflux disease in asthma and chronic obstructive pulmonary disease. Aliment Pharmacol Ther 2018; 47:176.</a></li><li><a class="nounderline abstract_t">Benson VS, Müllerová H, Vestbo J, et al. Associations between gastro-oesophageal reflux, its management and exacerbations of chronic obstructive pulmonary disease. Respir Med 2015; 109:1147.</a></li><li><a class="nounderline abstract_t">Ingebrigtsen TS, Marott JL, Vestbo J, et al. Gastro-esophageal reflux disease and exacerbations in chronic obstructive pulmonary disease. Respirology 2015; 20:101.</a></li><li><a class="nounderline abstract_t">Kunik ME, Roundy K, Veazey C, et al. Surprisingly high prevalence of anxiety and depression in chronic breathing disorders. Chest 2005; 127:1205.</a></li><li><a class="nounderline abstract_t">Coventry PA, Hind D. Comprehensive pulmonary rehabilitation for anxiety and depression in adults with chronic obstructive pulmonary disease: Systematic review and meta-analysis. J Psychosom Res 2007; 63:551.</a></li><li><a class="nounderline abstract_t">Schou L, Østergaard B, Rasmussen LS, et al. Cognitive dysfunction in patients with chronic obstructive pulmonary disease--a systematic review. Respir Med 2012; 106:1071.</a></li><li><a class="nounderline abstract_t">Torres-Sánchez I, Rodríguez-Alzueta E, Cabrera-Martos I, et al. Cognitive impairment in COPD: a systematic review. J Bras Pneumol 2015; 41:182.</a></li><li><a class="nounderline abstract_t">Cleutjens FA, Franssen FM, Spruit MA, et al. Domain-specific cognitive impairment in patients with COPD and control subjects. Int J Chron Obstruct Pulmon Dis 2017; 12:1.</a></li></ol></div><div id="topicVersionRevision">Topic 1439 Version 53.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://goldcopd.org/" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management , and prevention of chronic obstructive pulmonary disease (2018 Report). https://goldcopd.org/ (Accessed on October 28, 2018).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25411775" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Trends in mortality from COPD among adults in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25411775" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Trends in mortality from COPD among adults in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14999112" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20348199" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : COPD performance measures: missing opportunities for improving care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11073020" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Histamine airway hyper-responsiveness and mortality from chronic obstructive pulmonary disease: a cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10691587" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Increased susceptibility to pulmonary emphysema among HIV-seropositive smokers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12684248" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Airway bacterial load and FEV1 decline in patients with chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16778269" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Use of peak oxygen consumption in predicting physical function and quality of life in COPD patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17053205" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18641094" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Continuous oxygen use in nonhypoxemic emphysema patients identifies a high-risk subset of patients: retrospective analysis of the National Emphysema Treatment Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19047315" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Sex differences in mortality in patients with COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19342411" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The natural history of chronic airflow obstruction revisited: an analysis of the Framingham offspring cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20382712" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : CT scan findings of emphysema predict mortality in COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35579519" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Emphysema Progression at CT by Deep Learning Predicts Functional Impairment and Mortality: Results from the COPDGene Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35666811" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Chronic Bronchial Infection Is Associated with More Rapid Lung Function Decline in Chronic Obstructive Pulmonary Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35969416" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Diffusing Capacity and Mortality in Chronic Obstructive Pulmonary Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37159910" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Causes of and Clinical Features Associated with Death in Tobacco Cigarette Users by Lung Function Impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/453709" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Predictors of mortality in chronic obstructive pulmonary disease. A 15-year follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21991892" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Changes in forced expiratory volume in 1 second over time in COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22561963" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Spirometric predictors of lung function decline and mortality in early chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25211048" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Survival in COPD: impact of lung dysfunction and comorbidities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26154786" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21836135" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The progression of chronic obstructive pulmonary disease is heterogeneous: the experience of the BODE cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22016444" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16354849" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : A multidimensional grading system (BODE index) as predictor of hospitalization for COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18535255" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Longitudinal change in the BODE index predicts mortality in severe emphysema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2658702" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Body weight in chronic obstructive pulmonary disease. The National Institutes of Health Intermittent Positive-Pressure Breathing Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8630580" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Nutritional status and mortality in chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9620907" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10588597" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Prognostic value of nutritional status in chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12358326" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Prognostic value of weight change in chronic obstructive pulmonary disease: results from the Copenhagen City Heart Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16368793" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Body mass, fat-free body mass, and prognosis in patients with chronic obstructive pulmonary disease from a random population sample: findings from the Copenhagen City Heart Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17505043" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Body mass and fat-free mass indices in COPD: relation with variables expressing disease severity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36470414" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Differential Impact of Low Fat-Free Mass in People With COPD Based on BMI Classifications: Results From the COPD and Systemic Consequences-Comorbidities Network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31091375" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Muco-Obstructive Lung Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33180550" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Mucus Plugs and Emphysema in the Pathophysiology of Airflow Obstruction and Hypoxemia in Smokers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32017932" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Luminal Plugging on Chest CT Scan: Association With Lung Function, Quality of Life, and COPD Clinical Phenotypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17556723" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Survival after lung volume reduction in chronic obstructive pulmonary disease: insights from small airway pathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37210745" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Airway-Occluding Mucus Plugs and Mortality in Patients With Chronic Obstructive Pulmonary Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27345171" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Airway hyperresponsiveness in chronic obstructive pulmonary disease: A marker of asthma-chronic obstructive pulmonary disease overlap syndrome?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8665038" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Methacholine reactivity predicts changes in lung function over time in smokers with early chronic obstructive pulmonary disease. The Lung Health Study Research Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16543549" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Predictors of mortality in patients with emphysema and severe airflow obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36736486" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Stronger Associations of Centrilobular Than Paraseptal Emphysema With Longitudinal Changes in Diffusing Capacity and Mortality in COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36423926" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Mortality in non-exacerbating COPD: a longitudinal analysis of UK primary care data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16055870" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Factors affecting survival of hospitalised patients with COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12767954" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : In-hospital mortality following acute exacerbations of chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8887592" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9217591" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Reversible hypercapnia in chronic obstructive pulmonary disease: a distinct pattern of respiratory failure with a favorable prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7105857" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : The prognosis of patients with chronic obstructive pulmonary disease after hospitalization for acute respiratory failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2669584" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Survival data in patients with acute and chronic lung disease requiring mechanical ventilation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7500534" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11809986" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Acute respiratory failure secondary to chronic obstructive pulmonary disease treated in the intensive care unit: a long term follow up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34535466" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Risk prediction of covid-19 related death and hospital admission in adults after covid-19 vaccination: national prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34614553" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Outcomes of Patients with COPD Hospitalized for Coronavirus Disease 2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33758801" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : COPD and the risk of poor outcomes in COVID-19: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33631305" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Impact of the influenza vaccine on COVID-19 infection rates and severity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24064740" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Longitudinal association of C-reactive protein and lung function over 13 years: The EPIC-Norfolk study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18339787" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : C-reactive protein levels and survival in patients with moderate to very severe COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17426210" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Copeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20089972" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Percent emphysema, airflow obstruction, and impaired left ventricular filling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20190002" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Decreasing cardiac chamber sizes and associated heart dysfunction in COPD: role of hyperinflation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24473329" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Coronary artery calcification is increased in patients with COPD and associated with increased morbidity and mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26414484" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Chronic Obstructive Pulmonary Disease and the Risk of Stroke. The Rotterdam Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27189132" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : A Meta-Analysis of the Association of Chronic Obstructive Pulmonary Disease with Abdominal Aortic Aneurysm Presence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29723057" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Myocardial Infarction and Ischemic Stroke after Exacerbations of Chronic Obstructive Pulmonary Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20871122" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26044811" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Comorbidity between chronic obstructive pulmonary disease and type 2 diabetes: A nation-wide cohort twin study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19903974" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Chronic renal failure: a neglected comorbidity of COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19581353" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20935108" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Radiographic emphysema predicts low bone mineral density in a tobacco-exposed cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25719895" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Reduced Bone Density and Vertebral Fractures in Smokers. Men and COPD Patients at Increased Risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31352034" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Prevalence and Risk Factors for Osteoporosis in Individuals With COPD: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3965263" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Prevalence of depression and anxiety in patients with COPD. Relationship to functional capacity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19635280" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Depression and health-related quality of life in chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19801582" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : COPD and the risk of depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19933374" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : The impact of disability on depression among individuals with COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24395127" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Association of depression with disease severity in patients with chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20889909" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Determinants of depression in the ECLIPSE chronic obstructive pulmonary disease cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23229754" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Clinical usefulness of the two-question assessment tool for depressive symptoms in Japanese patients with chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19938969" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Screening for depression in chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27900466" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Overview of the Impact of Depression and Anxiety in Chronic Obstructive Pulmonary Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19423714" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Cognitive decline among patients with chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24182702" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Chronic obstructive pulmonary disease and association with mild cognitive impairment: the Mayo Clinic Study of Aging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24637951" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : A prospective study of chronic obstructive pulmonary disease and the risk for mild cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25285360" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Chronic obstructive pulmonary disease, cognitive impairment, and development of disability: the health and retirement study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29966745" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : The pharmacological treatment of chronic comorbidities in COPD: mind the gap!</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28076701" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Reduced Expiratory Flow Rate among Heavy Smokers Increases Lung Cancer Risk. Results from the National Lung Screening Trial-American College of Radiology Imaging Network Cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26363803" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : The relationship between COPD and lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25522175" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Lung cancer in patients with chronic obstructive pulmonary disease. Development and validation of the COPD Lung Cancer Screening Score.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35007497" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Control of Cardiovascular Risk Factors in Patients with Chronic Obstructive Pulmonary Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26208998" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34905461" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Differences in Outcomes between Heart Failure Phenotypes in Patients with Coexistent Chronic Obstructive Pulmonary Disease: A Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15860516" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18467897" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Detection of acute heart failure in chronic obstructive pulmonary disease patients: role of B-type natriuretic peptide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26781000" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Cardiac dysfunction during exacerbations of chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27532739" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Peripheral Artery Disease and Its Clinical Relevance in Patients with Chronic Obstructive Pulmonary Disease in the COPD and Systemic Consequences-Comorbidities Network Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22561964" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25515647" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : The relationship between sleep quality and functional exercise capacity in COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26914392" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : The Prevalence of Metabolic Syndrome In Chronic Obstructive Pulmonary Disease: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28489768" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Prevalence of comorbidities in chronic obstructive pulmonary disease patients: A meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18579551" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27118874" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Is Renal Impairment an Anticipated COPD Comorbidity?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29193245" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Review article: gastro-oesophageal reflux disease in asthma and chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26166017" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Associations between gastro-oesophageal reflux, its management and exacerbations of chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25297724" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Gastro-esophageal reflux disease and exacerbations in chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15821196" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Surprisingly high prevalence of anxiety and depression in chronic breathing disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17980230" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Comprehensive pulmonary rehabilitation for anxiety and depression in adults with chronic obstructive pulmonary disease: Systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22579108" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Cognitive dysfunction in patients with chronic obstructive pulmonary disease--a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25909154" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Cognitive impairment in COPD: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28031706" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Domain-specific cognitive impairment in patients with COPD and control subjects.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
